


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I



in which

R^2 , R^4 denote H, A, Hal, cycloalkyl having 3 to 7 C atoms, CF_3 , NO_2 , CN, OCF_3 , OA, NHA, NA_2 , or NH_2 ,

R^6 is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl,

R^3 is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl,







R^1 denotes H or CO_2R^5 , $(CH_2)_nCOHet$, CHO, $(CH_2)_nOR^5$, $(CH_2)_nHet$, $(CH_2)_nN(R^5)_2$, $CH=N-OA$, $CH_2CH=N-OA$, $(CH_2)_nNHOA$, $(CH_2)_n(R^5)Het$, $(CH_2)_nCH=N-Het$, $(CH_2)_nOCOR'$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2OCF_3$,

















$(\text{CH}_2)_n\text{N}(\text{R}^5)\text{C}(\text{R}^5)\text{OCOR}^5$, $(\text{CH}_2)_n\text{N}(\text{R}')\text{CH}_2\text{COHet}$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{Het}$,
 $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{Het}$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}')\text{CH}_2\text{OCOR}'$,
 $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}^5)_2$, $\text{CH}=\text{CHCOOR}^5$, $\text{CH}=\text{CHCH}_2\text{NR}^5\text{Het}$, $\text{CH}=\text{CHCH}_2\text{N}(\text{R}^5)_2$,
 $\text{CH}=\text{CHCH}_2\text{OR}^5$ or $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{Ar}$,















R^5 denotes H or A

















A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,















Het is 1-piperidyl, 1-piperazyl, 1-(4-methyl)piperazyl, 1-(4-ethyl)piperazyl, 1-(4-cyclopentyl)piperazyl, 4-methylpiperazin-1-ylamine, 1-pyrrolidinyl, 1-pyrazolidinyl, 1-(2-methyl)pyrazolidinyl, 1-imidazolidinyl or 1-(3-methyl)imidazolidinyl or 4-pyridyl, which is unsubstituted or substituted by one or more CN group, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, or a group of one of the formulae below


	
	
	



Ar denotes a phenyl radical which is unsubstituted or mono or polysubstituted by A and/or Hal, OR^5 , OOCR^5 , COOR^5 , $\text{CON}(\text{R}^5)_2$, CN, NO_2 , NH_2 , NHCOR^5 , CF_3 or SO_2CH_3 ,

X denotes CH or N,

n denotes 0, 1, 2, 3, 4 or 5 and

Hal denotes F, Cl, Br or I,

where, in the case that X has the meaning CH, R^2 and R^4 do not simultaneously denote H,

or a salt, enantiomer, or racemate thereof, or a mixture of enantiomers.

2. (Cancelled)




3. (Previously Presented) A compound according to claim 1, in which R^4 denotes H, Hal, CN, A or NO_2 .




4. (Previously Presented) A compound according to claim 1, in which R^2 denotes H or alkyl.

5. (Cancelled)

6. (Previously Presented) A compound according to claim 1, in which X has the meaning N.

7. (Previously Presented) A compound of formula IA, IB, IC, ID, IE or IF:






in which

R^3 , R^4 , R^6 and X have the meanings indicated for the compound of formula I.


8. (Previously Presented) A process for preparing a compound of claim 1, which is of formula IA



in which R^3 , R^4 , R^6 , X and A have the meaning indicated for the compound of formula I


or a salt thereof,

comprising reacting a compound of formula II




or an acid-addition salt thereof,

in which R⁴, R⁶ and X have the meanings indicated for the compound of formula I,
with a compound of formula III




in which A and R³ have the meanings indicated for the compound of formula I,
and/or converting a basic compound of formula IA into one of its salts by treatment with an acid.


9. (Previously Presented) A process for preparing a compound of claim 1, which is of formula IB



in which R^3 , R^4 , R^6 , X and A have the meaning indicated for the compound of formula I or a salt thereof,
comprising reacting a compound of formula II



or an acid-addition salt thereof,
in which R^4 , R^6 and X have the meanings indicated for the compound of formula I,
with a compound of formula IV



in which A and R^3 have the meanings indicated for the compound of formula I,
and/or converting a basic compound of formula IB into one of its salts by treatment with an acid.

10-13. (Cancelled)


14. (Previously Presented) A pharmaceutical composition comprising at least one compound of the formula I according to claim 1 and/or one of its physiologically acceptable salts, and a pharmaceutically acceptable carrier.

15. (Previously Presented) A process for the preparation of a pharmaceutical composition, comprising combining a compound of the formula I according to Claim 1 and/or one of its physiological acceptable salts into a suitable dosage

form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

16. (Cancelled)

17. (Previously Presented) A compound according to claim 1, in which Het is



18. (Cancelled)

19. (Previously Presented) A method for the *in vitro* inhibition of 5-HT_{2A} receptor, comprising administering to said receptor a compound, salt, enantiomer, racemate or enantiomer mixture of claim 1.

20. (Previously Presented) A compound according to claim 1, in which R¹ denotes denotes H or (CH₂)_nCOHet, CHO, (CH₂)_nOR⁵, (CH₂)_nHet, (CH₂)_n(R⁵)₂, CH=N-OA, CH₂CH=N-OA, (CH₂)_nNHOA, (CH₂)_n(R⁵)Het, (CH₂)_nCH=N-Het, (CH₂)_nOCOR', (CH₂)_nN(R⁵)CH₂CH₂OR⁵, (CH₂)_nN(R⁵)CH₂CH₂OCF₃, (CH₂)_nN(R⁵)C(R⁵)OCOR⁵, (CH₂)_nN(R')CH₂COHet, (CH₂)_nN(R⁵)CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂Het,

$(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}')\text{CH}_2\text{OCOR}'$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}^5)_2$, $\text{CH}=\text{CHCOOR}^5$,
 $\text{CH}=\text{CHCH}_2\text{NR}^5\text{Het}$, $\text{CH}=\text{CHCH}_2\text{N}(\text{R}^5)_2$, $\text{CH}=\text{CHCH}_2\text{OR}^5$ or $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{Ar}$.

21. (Previously Presented) A compound according to claim 1, in which R^1 denotes denotes H or CO_2R^5 , COHet , CHO , $(\text{CH}_2)_n\text{OR}^5$, $(\text{CH}_2)_n\text{Het}$, $(\text{CH}_2)_n\text{N}(\text{R}^5)_2$, $\text{CH}=\text{N-OA}$, $\text{CH}_2\text{CH}=\text{N-OA}$, $(\text{CH}_2)_n\text{NHOA}$, $(\text{CH}_2)_n(\text{R}^5)\text{Het}$, $(\text{CH}_2)_n\text{CH}=\text{N-Het}$, $(\text{CH}_2)_n\text{OCOR}'$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{OR}^5$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{OCF}_3$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{C}(\text{R}^5)\text{OCOR}^5$, $(\text{CH}_2)_n\text{N}(\text{R}')\text{CH}_2\text{COHet}$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{Het}$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{Het}$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}')\text{CH}_2\text{OCOR}'$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}^5)_2$, $\text{CH}=\text{CHCOOR}^5$, $\text{CH}=\text{CHCH}_2\text{NR}^5\text{Het}$, $\text{CH}=\text{CHCH}_2\text{N}(\text{R}^5)_2$, $\text{CH}=\text{CHCH}_2\text{OR}^5$ or $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{Ar}$.

22. (Previously Presented) A compound according to claim 1, in which R^1 denotes denotes H or $(\text{CH}_2)_n\text{Het}$, $(\text{CH}_2)_n\text{N}(\text{R}^5)_2$, $\text{CH}=\text{N-OA}$, $\text{CH}_2\text{CH}=\text{N-OA}$, $(\text{CH}_2)_n\text{NHOA}$, $(\text{CH}_2)_n(\text{R}^5)\text{Het}$, $(\text{CH}_2)_n\text{CH}=\text{N-Het}$, $(\text{CH}_2)_n\text{OCOR}'$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{OR}^5$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{OCF}_3$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{C}(\text{R}^5)\text{OCOR}^5$, $(\text{CH}_2)_n\text{N}(\text{R}')\text{CH}_2\text{COHet}$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{Het}$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{Het}$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}')\text{CH}_2\text{OCOR}'$, $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}^5)_2$, $\text{CH}=\text{CHCOOR}^5$, $\text{CH}=\text{CHCH}_2\text{NR}^5\text{Het}$, $\text{CH}=\text{CHCH}_2\text{N}(\text{R}^5)_2$, $\text{CH}=\text{CHCH}_2\text{OR}^5$ or $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{Ar}$.

23. (Previously Presented) A compound according to claim 1 or a pharmaceutically acceptable salt thereof.

24. (New) A compound according to claim 1, in which R^3 is thiophen-2-yl or thiophen-3-yl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl.

25. (New) A compound according to claim 1, in which R^3 is 2- or 3-furanyl.